Episode Details

Back to Episodes
A Steroid Injection During Glaucoma Surgery Was Linked to Dangerous Low Eye Pressure — What a New Randomized Trial Found

A Steroid Injection During Glaucoma Surgery Was Linked to Dangerous Low Eye Pressure — What a New Randomized Trial Found

Published 1 week, 5 days ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/a-steroid-injection-during-glaucoma-surgery-was-linked-to-dangerous-low-eye-pressure-what-a-new-randomized-trial-found

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

A Steroid Injection During Glaucoma Surgery Was Linked to Dangerous Low Eye Pressure — What a New Randomized Trial Found Research checked through November 4, 2026. A small randomized trial published on October 29, 2026, raised a serious safety question: could a long-acting steroid injection given during glaucoma drainage-device surgery suppress healing so much that the eye drains too freely? In the trial, late-onset low eye pressure occurred in 10 of 19 eyes given triamcinolone around the implant, compared with none of 20 control eyes. Seven of the 10 affected eyes needed another operation. That is a striking signal—but it does not show that ordinary steroid eye drops after glaucoma surgery are dangerous, nor that every drainage device or steroid regimen carries the same risk. The study tested one 20-milligram depot injection with one non-valved implant, in a small group of people with difficult-to-control glaucoma. Important details about the pressure threshold, the timing of individual cases, and their recovery are not reported in the publicly available abstract or registry. Trial report on PubMed Trial record on ReBEC What the new randomized trial tested Treatment, injection location, and masking The study included 39 eyes from 39 people with refractory primary open-angle glaucoma. All were undergoing Susanna UF glaucoma drainage-device surgery; the registry says participants had failed at least one prior trabeculectomy. Twenty eyes were assigned to the device alone, and 19 to the device plus triamcinolone. Follow-up lasted six months. The journal describes the study as multicenter and randomized. Trial report on PubMed Trial record on ReBEC The triamcinolone was 20 milligrams: 0.5 milliliters of a 40-milligram-per-milliliter suspension. It was injected into the sub-Tenon’s space around the implant plate, immediately before the conjunctiva—the tissue covering the white of the eye—was closed. This is a depot injection beside the implant, not an injection into the inside of the eye. Trial record on ReBEC The published abstract says that patients and outcome assessors were masked. The registry says a sham injection might have been used to mask the surgeon, but also allows that no sham was performed. So, based on the public records, surgeon masking cannot be confirmed. The registry also does not provide the full surgical recipe: it does not establish whether the tube was tied, fenestrated, or internally stented, or whether mitomycin C was used. Those details matter because they can change how much fluid flows through the device. Trial report on PubMed Trial record on ReBEC There are two further cautions. The registry lists a target of 48 participants, but only 39 were enrolled; recruitment stopped early because of safety concerns. It also records a first enrollment date in December 2020 and a public registration date in July 2025. Late public registration does not prove that results were reported selectively, but it limits confidence that every outcome and analysis was publicly specified before enrollment began. All 39 enrolled participants completed six-month follow-up. Trial record on ReBEC What the trial found For the full table, please open this article on visualfieldtest.com. The injection did not provide an additio

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us